Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

27.46 +2.08 (+8.20%)
Streaming Delayed Price Updated: 12:40 PM EDT, Jun 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tvardi Therapeutics, Inc. - Common Stock

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
Via Benzinga
This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.